Norges Bank Apellis Pharmaceuticals, Inc. Transaction History

Norges Bank

$716 Trillion
Q3 2024

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $41.1 Million - $64.5 Million	1,079,605 New	1,079,605 $41.4 Million
Q4 2023 Feb 09, 2024	BUY	$37.14 - $64.82 $35.1 Million - $61.3 Million	946,213 New	946,213 $56.6 Million
Q3 2023 Nov 13, 2024	BUY	$23.65 - $89.22 $24.9 Million - $93.9 Million	1,052,193 New	1,052,193 $40 Million
Q3 2023 Nov 13, 2023	SELL	$23.65 - $89.22 $23 Million - $86.8 Million	-972,974 Closed	0 $0
Q2 2023 Aug 14, 2024	SELL	$76.68 - $93.31 $4.34 Million - $5.28 Million	-56,579 Reduced 5.24%	1,023,026 $93.2 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $72.5 Million - $88.3 Million	-945,880 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$46.59 - $66.96 $43.4 Million - $62.4 Million	931,510 New	931,510 $61.4 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $45.3 Million - $63.9 Million	1,047,454 New	1,047,454 $54.2 Million
Q3 2022 Nov 13, 2023	BUY	$44.76 - $69.66 $43.6 Million - $67.8 Million	972,974 New	972,974 $66.5 Million
Q2 2022 Aug 14, 2023	BUY	$35.07 - $59.21 $33.2 Million - $56 Million	945,880 New	945,880 $42.8 Million
Q1 2022 May 12, 2023	SELL	$35.46 - $54.12 $8.24 Million - $12.6 Million	-232,489 Reduced 22.2%	814,965 $41.4 Million
Q1 2022 May 09, 2022	SELL	$35.46 - $54.12 $22.7 Million - $34.6 Million	-640,167 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$30.74 - $49.16 $19.7 Million - $31.5 Million	640,167 New	640,167 $30.3 Million
Q3 2021 Nov 14, 2022	BUY	$31.4 - $69.84 $16 Million - $35.6 Million	510,178 New	510,178 $16.8 Million
Q3 2021 Nov 05, 2021	SELL	$31.4 - $69.84 $13.9 Million - $30.9 Million	-441,861 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$40.9 - $64.9 $18.1 Million - $28.7 Million	441,861 New	441,861 $27.9 Million
Q2 2021 Aug 10, 2021	SELL	$40.9 - $64.9 $21 Million - $33.3 Million	-513,050 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$40.8 - $57.39 $20.9 Million - $29.4 Million	513,050 New	513,050 $22 Million
Q1 2021 May 07, 2021	SELL	$40.8 - $57.39 $27 Million - $38 Million	-662,697 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$30.79 - $57.2 $20.4 Million - $37.9 Million	662,697 New	662,697 $37.9 Million
Q4 2020 Feb 10, 2021	SELL	$30.79 - $57.2 $19.8 Million - $36.8 Million	-642,791 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$25.89 - $33.65 $16.6 Million - $21.6 Million	642,791 New	642,791 $19.4 Million
Q3 2020 Nov 10, 2020	SELL	$25.89 - $33.65 $2.71 Million - $3.52 Million	-104,687 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$24.8 - $38.49 $2.6 Million - $4.03 Million	104,687 New	104,687 $3.42 Million
Q2 2020 Aug 07, 2020	SELL	$24.8 - $38.49 $9.55 Million - $14.8 Million	-385,000 Closed	0 $0
Q1 2020 May 07, 2021	BUY	$17.91 - $44.33 $6.9 Million - $17.1 Million	385,000 New	385,000 $10.3 Million
Q2 2018 Jul 23, 2018	SELL	$19.63 - $30.0 $1.47 Million - $2.25 Million	-75,000 Closed	0 $0
Q1 2018 May 15, 2019	BUY	$14.01 - $26.02 $1.05 Million - $1.95 Million	75,000 New	75,000 $1.66 Million
Q1 2018 May 09, 2018	SELL	$14.01 - $26.02 $1.05 Million - $1.95 Million	-75,000 Closed	0 $0
Q4 2017 Mar 05, 2018	BUY	$12.71 - $21.7 $953,250 - $1.63 Million	75,000	75,000 $1.63 Million

Others Institutions Holding APLS

# of Institutions

310

Shares Held

113M

Call Options Held

3.85M

Put Options Held

1.09M

Wellington Management Group LLP Boston, MA

15.6M
Shares

$473 Million
0.08% of portfolio
Eco R1 Capital, LLC San Francisco, CA

11.9M
Shares

$361 Million
14.88% of portfolio
Avoro Capital Advisors LLC New York, NY

11.1M
Shares

$338 Million
4.82% of portfolio
Vanguard Group Inc Valley Forge, PA

9.82M
Shares

$298 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.8M
Shares

$176 Million
0.01% of portfolio

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.34B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account